Sustainability at Bayer is an integral part of a corporate policy geared to long-term success and innovative solutions. This commitment is also evidenced by the company’s participation in numerous initiatives and projects around the world.
Bayer has long practiced the concept of Responsible Care™. To achieve continuous improvement in the areas of health, safety and environment, the company has been guided by the principles of the voluntary Responsible Care initiative of the chemical and pharmaceutical industry since 1994 and by the Responsible Care Global Charter, which was last revised in 2006.
A member of the World Business Council for Sustainable Development since 1997, Bayer was a co-founder of German industry’s sustainable development forum “econsense” in 2000.
Bayer is a founding member of the United Nations Global Compact (UNGC) initiative, also established in 2000, actively promoting the 10 principles of the UNGC – for example through its involvement in the corporate sustainability leadership platform LEAD and the “Caring for Climate” and “CEO Water Mandate” initiatives.
For more than 50 years, Bayer has supported family planning programs in over 130 countries, focusing on cooperation with private and public relief organizations such as the United Nations Population Fund (UNFPA) and the United States Agency for International Development (USAID). Since January 2013, an innovative partnership between Bayer HealthCare and the Bill & Melinda Gates Foundation has guaranteed access to safe and reversible contraception for at least 27 million women in developing countries over a six-year period. As part of our partnership with the U.S. NGO, the White Ribbon Alliance (WRA), we make a joint contribution to the U.N.’s “Every Woman Every Child” campaign. Its goal is to work at local level to reduce the mortality rate of mothers, infants and children.
Activities in the area of family planning also include educating teenagers on sexuality and health issues. In Kenya, for example, Bayer cooperates with the German Foundation for World Population (DSW) in this field. In the fight against river blindness, Bayer is cooperating with Drugs for Neglected Diseases initiative (DNDi), a non-profit organization, with the aim of developing a new oral drug to treat river blindness (or onchocerciasis).
To effectively address the wide-ranging challenges of a sustainable supply chain and draw up industrial standards, Bayer has continued to intensively pursue joint approaches in the “Together for Sustainability” (TfS) initiative of the chemical industry and the Pharmaceutical Supply Chain Initiative (PSCI).
Our sustainability reporting is based on the guidelines of the Global Reporting Initiative (GRI). Bayer actively supports GRI as a Gold Community member.